HemostOD secures CHF 4.3 million to advance donor-free platelet manufacturing
HemostOD, a Swiss preclinical-stage company developing ex vivo manufactured universal human blood platelets, has closed a CHF 4.3 million seed extension financing round to advance pre-IND development and establish commercial-scale production capabilities. The funding round was co-led by Polytech Ventures and Orenok Holdings, with participation from the Lichtsteiner Foundation and private investors.


